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Abstract
Background:  Despite the importance of the BCL2L11 (BIM) protein in various apoptotic
processes in development and disease, little is known of the promoter structure of the human
BCL2L11 locus and of the cis-acting elements regulating expression of the human gene.
Results: In the search for novel promoter sequences in the human BCL2L11 locus, we have
identified previously unrecognized genomic sequences displaying promoter activity and E2F
responsiveness, and driving the expression of BCL2L11 coding transcripts. In man, transcripts
originating from this novel putative promoter contribute significantly to total BCL2L11 mRNA
expression in testis, heart and liver. In HEK293 cells, this novel candidate promoter originates
BCL2L11 transcripts whose expression can be modulated by a known modulator of BCL2L11
expression (Trichostatin A) and by E2F, a characterized transcriptional regulator of BCL2L11
expression.
Conclusion: The identification of a novel putative human BCL2L11 promoter provides new
insights into the structure and regulation of the BCL2L11 locus.
Background
The human BCL2L11 locus, located on chromosome
2q13, encodes a protein of 198 amino acids structurally
and functionally related to the BH3-only group of pro-
apoptotic BCL2 family members [3]. The gene is fre-
quently mutated in diverse human tumours leading to
loss of BCL2L11 activity [14,21]. Expression of BCL2L11
is induced by a diverse range of apoptotic stimuli such as
deprivation of growth factors/cytokines, ionizing radia-
tion, and cytotoxic peptides [2,6,14,22]. Although the reg-
ulation of BCL2L11 activity is highly complex and is cell
context-dependent, studies aimed at identifying the
molecular mechanisms underlying BCL2L11 activation
during apoptosis have revealed an important role for the
transcriptional regulation of BCL2L11 gene expression
[1,6,9,12,13,22,23]. A genomic region displaying pro-
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moter activity has been characterized for the human
BCL2L11 locus [13], while in the rat the existence of three
alternative promoter sequences has been postulated, the
most upstream of which corresponds to the promoter
described for the human BCL2L11 gene [2,3]. Regulation
of this conserved BCL2L11 promoter by FOXO and E2F
has been described using rat BCL2L11 genomic con-
structs, thus providing a likely mechanism for the induc-
tion of BCL2L11 expression during programmed cell
death [2,9], through the involvement of these transcrip-
tion factors whose activity is induced in apoptotic con-
texts. Whether regulation by E2F and FOXO factors is
conserved in humans remains to be demonstrated; how-
ever, such studies are hampered by the relatively poor
inter-specific sequence conservation in non-coding
sequences and the paucity of information on the structure
and regulation of the human BCL2L11 locus. We there-
fore set out to investigate the existence of as yet uncharac-
terized human BCL2L11 promoter regions, and to
determine the conservation from rodents to man of E2F
regulation of BCL2L11 expression.
Results
Identification of a novel putative BCL2L11 promoter 
region and associated BCL2L11 exon
In order to further investigate genomic sequences of the
human BCL2L11 locus with promoter activity, we first
applied a bioinformatics approach to identify clusters of
human ESTs with comparable 5' ends upstream of the first
coding exon of the human BCL2L11 locus, informative of
the possible existence of distinct transcript initiation sites.
We analyzed 13kb of human BCL2L11 genomic sequence
immediately upstream of the first BCL2L11 coding exon
by BLAST against the Genbank human EST database, and
identified 3 clusters with identical/comparable 5'ends
(Fig. 1A). The largest group (Group 2; 16 ESTs) corre-
sponded well to the human BCL2L11 promoter already
characterized (ca. 3 kb of genomic sequence upstream of
the BCL2L11 translational initiation codon), and con-
served between human and rat BCL2L11 loci [2,3]. A sec-
ond, more heterogeneous group (Fig. 1A; Group 3; 12
ESTs) localized to a region comprising sequences
described in the rat as potentially harbouring 2 alternative
promoters (ca. 1–2 kb upstream of the BCL2L11 transla-
tional initiation codon) [10]. A third group (Fig. 1A;
Group 1; 22 ESTs) localized to a region ca. 5.5 kb
upstream of the ATG, which did not correspond to known
BCL2L11 locus sequences in either man or rodents. This
group could be subdivided into two subgroups (Fig. 1B;
Group 1, subgroup A: 6 ESTs and Group 1, subgroup B: 16
ESTs), each with identical or nearly identical 5' ends,
apparently running in opposite directions and potentially
suggestive of the existence of a bidirectional promoter.
The first indication of the likely existence of an as yet
uncharacterized BCL2L11 promoter associated with novel
BCL2L11 untranslated exon sequences came from the
presence, within ESTs Group 2, of one EST (DB151955)
which clearly comprised the first BCL2L11 coding exon
(here called Exon 3), but not the first known BCL2L11
untranslated exon (here called Exon 2; Fig. 1B). Instead,
novel untranslated exon sequences 5' of the first known
untranslated BCL2L11 exon were present, which over-
lapped with Group 1 subgroup B ESTs. This was suggestive
of the presence of a novel BCL2L11 promoter and associ-
ated untranslated exon (here called P1 and Exon 1) 5' of
the most upstream known BCL2L11 promoter (here
called P2 and Exon 2). We therefore focused on Group 1
subgroup B ESTs, as these might represent novel BCL2L11
transcribed sequences by virtue of their overlapping with
EST DB151955, which comprises the first BCL2L11 cod-
ing exon (Exon 3). Their experimental association with
the first BCL2L11 coding exon (Exon 3) in a transcribed
sequence would in fact confirm the existence of a new
BCL2L11 promoter and associated untranslated exon.
Therefore, a series of RT-PCR experiments were performed
where the forward primer was anchored within Group 1
subgroup B ESTs and the reverse primer was anchored
within the first coding exon of the BCL2L11 locus, down-
stream of the translational initiation codon (primers indi-
cated by arrowheads in Fig. 1B). Complementary DNA
(cDNA) derived from HEK293 mRNA was used in these
experiments, as these cells were shown to express
BCL2L11 transcripts (this manuscript and data not
shown). The sequence of the resulting amplicons (Fig. 2A)
confirmed the presence of BCL2L11 coding sequences in
the amplified cDNA (Fig. 2B). The alignment (Fig. 2B) of
the obtained RT-PCR product sequences with DB151955
and with representative Group 1, subgroup B ESTs
(BM676697 and BP395271) confirmed the co-linearity of
these transcribed sequences. This finding confirmed that
Group 1, subgroup B ESTs indeed comprise novel
untranslated BCL2L11 sequences, thus identifying a novel
BCL2L11 untranslated exon (now called Exon 1) and con-
firming the existence of at least one novel putative
BCL2L11 promoter (P1) upstream of the previously char-
acterized human BCL2L11 promoter sequences ([3]; here
defined P2). Having ascertained that Group 1, Subgroup
B ESTs correspond to bona fide BCL2L11 transcripts, we
next sought to determine the 5' end of such transcripts in
order to determine a putative transcript initiation site,
defining a possible 5' exon boundary and a starting point
for the definition of a promoter region for P1. 5'RACE
experiments performed on HEK293 cells, using a reverse
primer anchored within the novel human BCL2L11 exon
(Exon 1) and overlapping with the forward primer used in
the RT-PCR studies described above, identified a sequence
around the 5' end of Group 1, subgroup B ESTs as the tran-
script initiation site in HEK293 cells (Fig. 3A and 3B), thus
defining the likely 5' boundary of this novel human
BCL2L11 exon and confirming the existence of a novelBMC Molecular Biology 2008, 9:56 http://www.biomedcentral.com/1471-2199/9/56
Page 3 of 16
(page number not for citation purposes)
Bioinformatics analysis recognizes known HsBCL2L11(BIM) promoters and identifies a putative promoter region upstream of  these Figure 1
Bioinformatics analysis recognizes known HsBCL2L11(BIM) promoters and identifies a putative promoter 
region upstream of these. A. BLAST analysis of 13 kb of genomic sequence upstream of HsBCL2L11 ATG codon 
(NT_022135.15|Hs2_22291, bases 576452 to 505224) vs Genbank ESTs identified transcribed regions upstream of BCL2L11 
locus. Three EST groups can be identified. Of these, groups 2 and 3 correspond to transcripts associated with published 
BCL2L11 promoters (2: human P2; ref. 13; 3: rat P3, ref. 9). Group 1 is not associated with any published vertebrate BCL2L11 
promoter sequences. B. Close-up of a ca. 5000 bp region comprising Group 1, 2 and 3 ESTs. The location of the BCL2L11 
ATG codon is indicated. One Group 2 EST (DB151955), comprising the first BCL2L11 coding exon, overlaps with Group 1, 
subgroup B ESTs. Arrowheads indicate the position of RT-PCR primers used to confirm the co-linearity of Group 1, subgroup 
B ESTs with the first BCL2L11 coding exon.
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A transcript originating from the BCL2L11-P1 region in HEK293 cell is a novel BCL2L11 transcript Figure 2
A transcript originating from the BCL2L11-P1 region in HEK293 cell is a novel BCL2L11 transcript. A. RT-PCR 
in HEK293 cDNA using a Forward primer anchored within Group 1, subgroup B ESTs and a Reverse primer anchored down-
stream of the translation initiation codon of HsBCL2L11; a ca. 1000 bp fragment (arrow) is amplified from HEK293 cells. For 
or Rev: single primer controls; CTRL refers to the no cDNA control. No amplification was observed when RNA was used as 
template (data not shown). B. Sequence of the amplified cDNA fragment and its alignment with ESTs from Group 1, subgroup 
B (BM676697, BP395271) and from Group 2 (DB151955). The first BCL2L11 coding exon is shaded in grey (BCL2L11 coding 
sequence in dark grey).
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A novel putative promoter is identified upstream of known BCL2L11 promoters Figure 3
A novel putative promoter is identified upstream of known BCL2L11 promoters. A. 5'-RACE on transcribed 
sequences in BCL2L11-P1 to identify transcript initiation sites in HEK293 cells; the major PCR product, indicated by the aster-
isk, was sequenced and defined the major transcript initiation site. For or Rev: single primer controls; CTRL refers to the no 
cDNA control. B. Sequence of the cloned BCL2L11-P1 region; the sequence shaded in grey indicates coverage by 16 independ-
ent human ESTs in Genbank. The arrow indicates the transcript initiation site identified in HEK293 cells by 5' RACE. The red 
box indicates the sequence of the reverse primer employed in the 5'RACE experiments.
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human BCL2L11 promoter. A diagram summarizing the
position of ESTs and of the RT-PCR and 5'RACE products
relatively to human BCL2L11 genomic sequences is pro-
vided in Fig. 4A. As transcripts originating from this region
do not contain sequences associated with the exon imme-
diately downstream of the published human BCL2L11
promoter ([3]; here called Exon 2), but splice directly onto
the first BCL2L11 coding exon ([3]; here called Exon 3), it
follows that the human BCL2L11 locus might comprise at
least two alternative promoters (P1, characterized in the
present manuscript, and P2) and that alternative splicing
occurs in the 5' untranslated exons. A third promoter
region (P3) may also exist based on data from the rodent
BCL2L11 locus [10]. Next, the capacity of P1 sequences to
drive gene expression was tested in a series of reporter
assays in HEK293 cells. A human genomic region of 2235
bp region comprising a portion of Exon 1 (including the
transcript initiation site, and upstream sequences to posi-
tion -1918 with respect to the HEK293 Exon 1 transcript
initiation site; henceforth defined as BCL2L11-P1-1918)
was therefore amplified, cloned, sequenced and sub-
cloned into the promoter-less luciferase reporter vector
pGL3Basic in both orientations, to give rise to the reporter
constructs pBCL2L11-P1-1918(+) and (-). The constructs
were then transiently transfected into HEK293 cells and
the resulting luciferase activity compared to basal
pGL3Basic activity (background control). The results (Fig.
4B) indicate that P1 sequences can drive gene expression,
as measured by luciferase activity, though independently
of their orientation. Although orientation-dependent
activity is usually considered a hallmark of promoter
sequences, examples of bona-fide bidirectional promoters
are known (e.g. see [8,17,18]). Therefore, P1 may repre-
sent a promoter with potential for bi-directional activity,
at least in HEK293 cells. This possibility is also supported
by the existence of Group 1, subgroup A ESTs as discussed
above (see also Fig. 1B), representing ESTs with similar 5'
ends but with apparently displaying sequences which are
complementary to the sense (with respect to the BCL2L11
locus) P1 direction and starting within ca. 50 bp of the
transcript initiation site of E1. Although the existence of a
bi-directional promoter in this genomic region is sup-
ported by our experimental data and from the existence of
coherent ESTs, further studies (e.g. 5'RACE to experimen-
tally identify the antisense transcript initiation sites of the
promoter and 3'RACE to clone the associated transcripts)
are required to confirm this possibility. As our interest was
on the identification of putative novel BCL2L11 promoter
sequences, this line was not pursued further.
Exon 1 containing transcripts are widely expressed in 
human tissues
In order to evaluate the possible significance of BCL2L11
transcripts originating from this novel candidate pro-
moter for overall BCL2L11 transcript expression in man,
the expression of BCL2L11 mRNAs bearing the alterna-
tively spliced Exon 1 or Exon 2 sequences, or of total
BCL2L11 transcripts, was evaluated in a panel of cDNAs
derived from human tissues by real-time PCR, using SYBR
green technology. Primer pairs specific for BCL2L11 Exon
1 or 2, or for a BCL2L11 transcribed region presumably
present in most characterized BCL2L11 transcripts (spe-
cific for a 3' region of BCL2L11 coding sequences) were
employed. The results indicated that transcripts originat-
ing from the candidate novel BCL2L11 promoter P1 were
readily detectable in a number of human tissues (Fig. 5A),
and contributed most significantly to BCL2L11 mRNA
levels in testis, heart and liver (by comparison with
BCL2L11 transcript levels detected with primers specific
for a 3' region of BCL2L11 coding sequences). Next, the
relative contribution of Exon 1- and Exon 2-containing
transcripts to total BCL2L11 expression in HEK293 cells
was then evaluated by real-time PCR, using SYBR green
technology. The results (Fig. 5B) again indicated that
BCL2L11 transcripts containing Exon 1 or Exon 2 are
expressed in HEK293 cells.
Exon 1 containing transcripts are coordinately and 
coherently regulated with other BCL2L11 transcripts by 
TSA in HEK293 cells
The biological significance of the newly identified puta-
tive BCL2L11 promoter would be further strengthened if
transcripts derived from it could be shown to be co-regu-
lated together with other BCL2L11 transcripts, in a cellu-
lar context where BCL2L11 mRNA levels are known to be
modulated. In order to investigate this possibility, the lev-
els of different BCL2L11 mRNAs were quantitatively
measured in cDNA from HEK293 cells or HEK293 cells
treated with a known inducer of BCL2L11 expression in
human cells, namely the histone deacetylase inhibitor Tri-
chostatin A (TSA) [15], using the primer pairs mentioned
above. In HEK293 cells, Exon 1 containing BCL2L11 tran-
scripts are rapidly and transiently induced by Trichostatin
A (TSA; Fig. 6A). In HEK293 cells, BCL2L11 transcripts
comprising Exon 2 sequences (and thus derived from P2)
are by far the most abundant (approximately 50 times
more abundant than Exon 1-containing transcripts; Fig.
6). Interestingly, the steady-state levels of human
BCL2L11 transcripts comprising Exons 1 and 2 are rapidly
and transiently increased by TSA, confirming the reported
regulation of BCL2L11 expression by this inhibitor of his-
tone deacetylases [15]. We next investigated the relative
contribution of BCL2L11 transcripts comprising Exons 1
and 2 to total BCL2L11 transcript levels (Fig. 6C). Exon 1-
containing transcripts display the same induction profile
of transcripts detected by a primer pair presumably recog-
nizing most known BCL2L11 transcripts (Fig. 6A and 6C).
Exon 2-containing transcripts account for the majority of
steady-state BCL2L11 transcripts in HEK293 cells. In
untreated HEK293 cells, the cumulative levels of steady-BMC Molecular Biology 2008, 9:56 http://www.biomedcentral.com/1471-2199/9/56
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A. Schematic summary of results Figure 4
A. Schematic summary of results. The human BCL2L11(BIM) locus is shown aligned with relevant ESTs and with the RT-PCR 
and 5'RACE products. For simplicity the alias BIM is used in the figure instead of the approved gene symbol BCL2L11. The 
transcript originating in the BIM promoter 1 region defines a novel BIM exon comprising sequences covered by Genbank ESTs 
and spliced onto the first coding exon of BIM. B. BIM-P1 sequences can drive transcription of a luciferase reporter when tran-
siently transfected in HEK293 cells. pBIM-P1 constructs (-1918 relatively to the HEK293 transcript initiation site) demonstrate 
that the sequence can drive transcription of the reporter in an orientation-independent manner. *p < 0.01, Anova: single fac-
tor.
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A. Real-time expression profiling of BCL2L11(BIM) transcripts as detected with primers specific for Exon 1 (E1), Exon 2 (E2)  or capable of recognizing the majority of BCL2L11 transcripts (BCL2L11 total) Figure 5
A. Real-time expression profiling of BCL2L11(BIM) transcripts as detected with primers specific for Exon 1 (E1), Exon 2 (E2) 
or capable of recognizing the majority of BCL2L11 transcripts (BCL2L11 total). For simplicity the alias BIM is used in the figure 
instead of the approved gene symbol BCL2L11. B. Expression of BIM P1- and P2-derived transcripts in HEK293 cells, and of 
BIM transcripts detected by primers capable of recognizing the majority of BIM transcripts (BIM total).
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Endogenous BCL2L11(BIM) transcripts comprising E1, E2 and 3'coding sequences are coordinately regulated by TSA in  HEK293 cells Figure 6
Endogenous BCL2L11(BIM) transcripts comprising E1, E2 and 3'coding sequences are coordinately regulated 
by TSA in HEK293 cells. For simplicity the alias BIM is used in the figure instead of the approved gene symbol BCL2L11. A. 
Time course of expression of Exon 1-containing BIM transcripts in HEK293 cells following TSA treatment as measured by real-
time PCR, using an E1-specific primer set (E1); TSA rapidly induces BIM-E1 expression at 4 hrs at both concentrations tested. 
B. The same analysis was performed using primer sets specific for the (previously known) BIM Exon 2; The expression of the 
P2-derived BIM transcript in HEK293 cells (E2) is induced by TSA at 4 hrs at the concentrations of 0.2 μM (i) and 1 μM (ii), as 
for E1 containing BIM transcripts. C. Time course of expression of BIM transcript levels in HEK293 cells treated with 0.2 μM 
TSA, and detected using primers specific for a 3' region of the coding sequence (and presumably recognizing most BIM tran-
scripts; Total) or primers specific for Exon 1- or Exon 2-bearing BIM transcripts (E1 or E2, respectively).
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BCL2L11(BIM)-P1 activity is regulated by E2F Figure 7
BCL2L11(BIM)-P1 activity is regulated by E2F. For simplicity the alias BIM is used in the figure instead of the approved 
gene symbol BIM. A. Inducibility of endogenous E1 and E2-bearing BIM transcripts by transiently transfected E2F expression 
construct in HEK293 cells; real-time experiments were performed as previously in cells transfected with either pBst or an E2F 
expression construct, and the fold inducibility (relatively to pBst transfected cells) of individual transcripts by the E2F expres-
sion plasmid is presented; the results confirm reporter data and show that the expression of endogenous BIM transcripts 
derived from P1 can be induced by E2F. *p < 0.01, Anova: single factor. B. Analysis of the effects of E2F overerexpression on 
pBIM-P1-1918(+) activity in HEK293 cells. A concentration-dependent inducibility of P1 activity is observed; by contrast, a ver-
sion of P1 comprising a 5' deletion of 1300 bp results in a promoter construct with a basal activity comparable to P1-1918, but 
without the capacity for E2F-mediated activation, suggesting the presence of E2F responsive elements in the deleted region. *p 
< 0.01, Anova: single factor.
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state BCL2L11 transcripts encoding Exons 1–2 are lower
than levels of steady-state BCL2L11 transcripts detected
using a primer set potentially recognizing most BCL2L11
transcripts (Fig. 5C), and account for approximately 60%
of these. These differences may result from differential sta-
bility of BCL2L11 transcripts bearing different 5'ends, or
from other as yet uncharacterized reasons such as the pres-
ence of further promoters in this locus. Collectively, these
expression data support the hypothesis that P1-derived
transcripts are a bona-fide human BCL2L11 mRNAs dis-
playing a pattern of regulation which is coherent with the
overall regulation of BCL2L11 expression by a known
small molecule modulator, at least in HEK293 cells.
E2F regulates the activity of BCL2L11-P1
E2F is a known regulator of BCL2L11 transcription during
apoptosis [2,11], as evidenced by studies performed on
the rat and mouse BCL2L11 loci. In order to determine if
E2F can regulate the expression of human BCL2L11 pro-
moters in HEK293 cells, the real time primers employed
above were used to measure levels of BCL2L11 transcripts
originating from the two known human promoters
(namely the novel promoter BCL2L11-P1 described here
and from the previously known promoter BCL2L11P2) in
response to transient transfection of a commercially avail-
able human E2F expression construct. This was made pos-
sible by the high transfection efficiency achieved in
HEK293 cells with standard lipofection-mediated meth-
odologies (>80%; data not shown). As indicated in Fig.
7A, overexpression of E2F results in a significant increase
in the steady-state levels of Exon 1-comprising transcripts,
suggestive of a role for E2F in regulating the transcription,
processing or stability of endogenous P1-derived tran-
scripts. In contrast, Exon 2-containing transcripts were not
affected, suggesting that the endogenous P2 is not signifi-
cantly modulated by E2F under these experimental condi-
tions. As the P2 promoter is regulated directly or indirectly
by E2F in rodents [2,11], our results suggest that this reg-
ulation may not be conserved in humans, at least under
these experimental conditions and in HEK293 cells. In
order to determine if E2F could directly regulate P1 activ-
ity, we next investigated the capacity of the E2F expression
plasmid to modulate the activity of BCL2L11-P1-1918
(Fig.7B). We observed an induction of reporter activity
with BCL2L11-P1-1918 which was dependent on the con-
centration of E2F expression plasmid. Conversely, we did
not observe such E2F inducibility with a 5' deletion vari-
ant of P1 lacking all but 350 bp of the genomic region
upstream of the transcript initiation site (BCL2L11-P1-
350). These data suggested that an E2F-responsive regula-
tory element is located within P1, between position -1918
and -350 bp. We therefore searched for candidate E2F
binding sites in the BCL2L11-P1-1918 sequence using a
web-based in silico algorithm, and identified a potential
E2F element at position -1309 (Fig. 8A). A number of 5'
deletion variants of BCL2L11-P1-1918 were therefore gen-
erated by proofreading PCR using the indicated forward
primers (Fig. 8A), and subsequently cloned into
pGL3Basic to generate the reporter constructs BCL2L11-
P1-1566, -1326, -1284, -940. These constructs were then
tested for regulation by overexpressed E2F in HEK293
cells, as described above. The results (Fig. 8B) indicated
that significant E2F inducibility was lost upon deletion of
a region of only 42 bp, located between positions -1326
and -1284, and comprising the candidate E2F binding site
located at position -1309. Direct proof of the interaction
between E2F and this candidate E2F binding site was
therefore sought by electromobility shift assays (EMSA). A
double stranded oligonucleotide corresponding to the
candidate E2F binding site was labeled and its capacity to
bind E2F was studied using nuclear extracts from HEK293
cells transiently transfected with the human E2F expres-
sion construct. Competitions with cold double stranded
oligonucleotides comprising either a canonical E2F bind-
ing site or a binding site for an irrelevant transcription fac-
tor (NF-κB) were used in order to determine the specificity
of the observed interaction. As shown in Fig. 9, a strong
bandshift (arrow) is observed using nuclear extracts from
HEK293 cells transfected with the E2F expression plas-
mid. A much weaker but identically migrating band is also
visible in nuclear extracts from untransfected HEK293
cells or from cells transfected with a control plasmid.
Competition with excess specific or unspecific competi-
tors indicates that the observed band is specifically com-
peted by an oligonucleotide comprising a canonical E2F
binding site (Fig. 9). Therefore, the genomic element
identified in BCL2L11-P1 at position -1309 as a potential
E2F binding site is indeed a functional E2F binding site
and provides a molecular basis for E2F regulation of
BCL2L11-P1.
Discussion
We have identified a novel putative promoter and associ-
ated exon of the human BCL2L11 locus in HEK293 cells
and showed regulation of this promoter by the transcrip-
tion factor E2F, which is known to modulate BCL2L11
transcription in other species. BCL2L11 transcripts
derived from this promoter are widely expressed in
human tissues, and contribute significantly to BCL2L11
expression in testis, heart and liver. The real-time PCR
data presented here constitutes the first systematic, quan-
titative analysis of steady-state BCL2L11 transcript expres-
sion levels in different human tissues. Overall, the data
obtained on the distribution of BCL2L11 mRNA levels in
different human tissues correlate with published data on
the distribution of BCL2L11 RNA and protein in human
tissues, which indicates relatively higher expression in tes-
tis and spleen [23,24], organs where BCL2L11 has recog-
nized functions in spermatogenesis and hematopoiesis,
respectively [25,26]. Interestingly, the analysis presentedBMC Molecular Biology 2008, 9:56 http://www.biomedcentral.com/1471-2199/9/56
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Effects of E2F on BCL2L11-P1 constructs Figure 8
Effects of E2F on BCL2L11-P1 constructs. For simplicity the alias BIM is used in the figure instead of the approved gene 
symbol BCL2L11. A. Sequence of the -1918 P1 region showing the position of 5' deletion variants. Forward primers used to 
generate the various P1 5' deletion variants are indicated (arrows). The putative E2F binding site is boxed, and the transcript 
initiation site is indicated (+1). B. Analysis of the effects of E2F over-expression on pBIM-P1 and 5'deletion variants activity in 
HEK293 cells. A concentration-dependent inducibility of P1 activity is observed in construct pBIM-P1-1918, -1565 and -1326, 
which contain a putative E2F responsive element. By contrast, pBIM-P1-1284 and -940 display basal activities comparable to 
pBCL2L11-P1-1918, but without the capacity for E2F-mediated response, suggesting a loss of E2F responsive element(s). *p < 
0.05 and **p < 0.01, Anova: single factor.
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in this manuscript indicates that the highest expression
levels of BCL2L11 transcripts were detected in pancreas,
placenta and thyroid tissue, suggesting an important role
for BCL2L11 in the normal physiology of these tissues.
With respect to P1-derived transcripts, up to 70% of total
BCL2L11 transcripts are contributed from the newly iden-
tified promoter in the testis, an organ where BCL2L11
activity was shown to contribute critically to sperma-
togenesis [25], suggestive for a prominent role for the
putative BCL2L11 P1 in the expression of BCL2L11 in this
tissue. Although the biological significance of BCL2L11
P1 remains to be determined, the expression of P1-
derived transcripts in various human tissues of relevance
to BCL2L11 biological function argues for a physiological
significance of such transcripts. The biological signifi-
cance of the newly identified putative BCL2L11 promoter
was strengthened by the observation that transcripts
derived from it could be shown to be co-regulated
together with other BCL2L11 transcripts by a known phar-
macological modulator of BCL2L11 expression (TSA), in
the same cell line where such transcripts have been iden-
tified. Another piece of circumstantial evidence pointing
to a physiological role for BCL2L11 P1 in BCL2L11
expression is its regulation by the transcription factor E2F.
Studies performed on the rodent BIM promoters (the
equivalents of BCL2L11 P2) have identified this transcrip-
tional regulator as a modulator of BCL2L11 expression
during apoptotic processes [2,11]. Through a combina-
tion of reporter assays and DNA-protein interaction stud-
ies, we were able to demonstrate that E2F can upregulate
BCL2L11 P1 activity in HEK293 cells through a cis-acting
element identified through a bioinformatics analysis,
which can bind E2F in EMSA assays and whose presence
is required for responsiveness to overexpressed E2F. This
is the first indication of direct transcriptional regulation of
a BCL2L11 promoter by E2F, as previous reports of E2F
involvement in the regulation of BCL2L11 expression
have shown either an indirect regulation through other
transcription factors [2] or have not investigated the
underlying mechanism [11]. The potential contribution
of P1 activity during BCL2L11-mediated apoptotic proc-
esses induced by E2F may therefore be physiologically
important and deserves further investigation. A number of
further aspects are worthy of further analysis. First, further
characterization of BCL2L11 P1 in different cellular con-
texts/backgrounds is required, in particular in contexts
where BCL2L11 expression is higher than that observed in
HEK293 cells where BCL2L11 expression is relatively low,
in order to confirm that such new putative promoter is
indeed generally active and drives BCL2L11 transcripts in
most situations where the locus is transcribed. Second, the
relative contribution of P1- and P2-derived transcripts to
BCL2L11 protein expression may differ and needs to be
investigated, as E1 and E2 are alternatively spliced and
may contribute differently to mRNA stability and transla-
tion. Finally, it remains to be determined if a homologue
of BCL2L11-P1 exists in rodents. Interestingly, a BLAST
analysis using 13 kb of mouse genomic sequences
upstream of the first coding exon of the murine BCL2L11
locus revealed a similar pattern of ESTs as that evidenced
in this manuscript for the human locus, suggesting the
potential existence of a BCL2L11-P1 homologue in mice
(data not shown) and providing further indirect evidence
of an important physiological role for P1 in BCL2L11
expression.
E2F binding to a candidate E2F binding site in BCL2L11-P1 Figure 9
E2F binding to a candidate E2F binding site in 
BCL2L11-P1. EMSA on the candidate E2F binding site 
(CTCTGCGCGCCAGAGG). HEK293 cells were trans-
fected with the E2F expression construct, and nuclear 
extracts were assayed for capacity for specific binding to the 
candidate E2F binding site through competition with a spe-
cific (E2F) or unspecific (NF-κB) unlabelled competitor dou-
ble stranded (ds) oligonucleotide. A specific shift is identified 
(arrow) upon transfection with the E2F expression plasmid, 
which can only be competed with a specific ds oligonucle-
otide.
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Conclusion
Through a combined bioinformatics and experimental
approach we have identified a novel putative promoter
and associated untranslated exon in the human BCL2L11
genomic locus, upstream of the previously characterized
promoter. This candidate promoter generates transcripts
which are widely expressed in human tissues, and which
contribute significantly to overall BCL2L11 expression in
tissues where BCL2L11 is known to play important phys-
iological roles, such as the testis. Our data are suggestive
of a complex pattern of transcriptional regulation of the
human BCL2L11 locus, comprising alternative promoter
usage and alternatively spliced 5' untranslated exons, and
suggests the presence of additional, as yet unidentified
promoter(s). Although, the general relevance and impact
of BCL2L11-P1 and of its regulation by E2F in other
human cell lines or in vivo remains to be determined, the
present study offers novel insights into the structure and
regulation of the human BCL2L11 locus.
Methods
Bioinformatics
Bioinformatics analyses were performed using tools avail-
able at NCBI [28]. E2F binding site prediction was per-
formed at GBF [29].
DNA and RNA extraction, cDNA synthesis and PCR 
amplification
Genomic DNA was isolated from HEK293 cells as
described [19]. Total RNA was isolated using a commer-
cial kit (RNeasy Kit, Quiagen, Hilden, Germany) as per
manufacturer's instructions. RNAs from human tissues
were obtained from a commercial source (Clontech Inc.,
CA). cDNA was synthesized from 2 μg total RNA using
Superscript II Reverse Transcriptase (Invitrogen) as per
manufacturer's instructions, using oligodT as a primer.
Preparative PCR was performed using Phusion DNA
polymerase from Finnzymes Inc (Espoo, Finland), as per
manufacturer's instructions.
Cloning and generation of plasmid constructs
All cloning and subcloning was performed using PCR
approaches as described in the text. For cloning and trans-
formation, One Shot TOP10 Chemically Competent E.
coli, Zero Blunt PCR Cloning Kit were from Invitrogen
(San Diego, CA) and were used as per manufacturer's
instructions. DNA manipulations were performed using
techniques essentially as described [19]. All PCR reactions
were performed using a proofreading polymerase (Phu-
sion polymerase, Finnzymes Inc.). Human genomic
sequences associated with the BCL2L11 locus were ampli-
fied from HEK293 genomic DNA using a specific primer
set and a nested PCR strategy (BCL2L11-P1-1918-FOR1
TAACAACATCAGTGCGGCTC and BCL2L11-P1-1918-
REV1 AGAGAACGCAGTGTGAGAAG, followed by a sec-
ond round using BCL2L11-P1-1918-FOR2 AAGAGCTCG-
GCTCAGACATCA and BCL2L11-P1-1918-REV2 AAAAGC
TTCACCTCCTTCGCG). A 2235 bp fragment comprising
the genomic region of interest was subcloned into
pGL3Basic (Promega Inc.) as a transcriptional fusion
(BCL2L11-P1-1918). Deletions construct of BCL2L11-P1-
1918 were prepared using following primer set BCL2L11-
P1-1566 FOR AAGAGCTCGGCATTGGCGTTAACAGC,
BCL2L11-P1-1326 FOR AAGAGCTCGCTCTTCCTGTTCA
GTTC, BCL2L11-P1-1284 FOR AAGAGCTCCCCAGGCAC
TCCAGAGGT, BCL2L11-P1-940 FOR AAGAGCTCAGCT-
GCTGTCACTAGATG and for all reactions BCL2L11-P1-
2000 REV AAAAGCTTCTCCCCACCCTCT. RT-PCR to
confirm the transcript originating from BCL2L11-P1
region was performed using the following primer set
HsBCL2L11E1-FOR1 TTCAGCACAAGCCATCCTCC and
HSBCL2L11-CDS-REV1 ACCTCCGTGATTGCCTTCAG.
All constructs were confirmed by DNA sequencing.
RT-PCR and RACE cDNA cloning
RT-PCR and RACE-PCR was performed essentially as
described previously [4]. First strand synthesis was per-
formed using Superscript II according to manufacturer's
instructions, employing 2 μg total RNA. 5' Rapid amplifi-
cation of cDNA ends (RACE) was carried out by reverse
transcription of HEK 293 cells polyadenilated (poly A)
RNA employing the primer, CCAGTGAGCAGAGTGACG
AGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTT, which
contains an anchor region. For RT-PCR, a forward primer
anchored to sequences present within Group 1, subgroup
A ESTs (BCL2L11-RT-FOR AGCACAAGCCATCCTCCTTC)
and a reverse primer anchored within the first BCL2L11
coding exon, 3' to the translational initiation codon
(BCL2L11-RT-REV TTGCCTTCAGGATTACCTTG) were
employed. For RACE-PCR, a nested amplification
approach was used, employing the following primer
BCL2L11-P1-RACE1 AGAGAACGCAGTGTGAGAAG and
the 5' anchored externally primer RACEA CCAGTGAGCA-
GAGTGACG. Conditions were as follows: annealing 62°C
for the first 10 cycles, then 40 cycles at 52°C (Dyad DNA
Engine, Biorad, USA). For second round the following
primer set was employed: BCL2L11-P1-RACE2 GGAG-
GATGGCTTGTGCTGAA and the primer anchored inter-
nally to RACEA, of sequence GAGGACTCGAGCTCAAGC
using the same amplification program of the first round.
The amplicon was loaded on a 1.5% gel, purified, and
finally cloned. Purification was done using PCR purifica-
tion kit (Quiagen, Hilden, Germany) and cloning in Zero
Blunt cloning kit. Sequences were confirmed by sequenc-
ing both strands of more than one clone (MWG, Martin-
sried). All primer sets yielding PCR products from cDNA
templates were tested for the absence of products resulting
from amplification using the corresponding RNA as a
template, to detect eventual problems due to genomic
DNA contamination (data not shown).BMC Molecular Biology 2008, 9:56 http://www.biomedcentral.com/1471-2199/9/56
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Cell culture
Human Hembrional Kidney cells (HEK293) were pro-
vided from ATCC and were grown at 37°C, 5% CO2 in
DMEM, medium (Gibco) supplemented with 10% fetal
bovin serum (Biowhittaker, Cambrex), 1% streptomycin
ampicillin (Cambrex) and 1% glutamax (Gibco). Trichos-
tatin A was from Sigma Chemical Company. A 10 mM
solution of TSA in dimethylsulphoxide was prepared and
stored a -20°C until use. HEK293 plated in 6 wells were
treated the day after with TSA 0.2 μM or 1 μM for 4, 8, 16,
24 hours. Control cells were treated with dimethylsul-
phoxide. At the end of incubation period cells were har-
vested. Total RNA extraction and cDNA synthesis were
performed as described before.
Transient transfections and luciferase assays
The human E2F expression construct was purchased from
a commercial source (Origene). DNA was prepared with
Plasmid Maxi kits (Qiagen, Hilden, Germany). HEK293
cells were cotransfected with 0.05 μg of reporter plasmid,
0.01 μg of Renilla vector (pRL-TK, Promega), 0.01 μg of
empty plasmid Bluescript (Stratagene, Inc.) or 0.1 or 0.05
μg Human E2F expression construct (Origene, Inc.) in 95
μl of serum-free medium per well in 96-well plate using
Lipofectamine 2000 [5]. Three hours later, medium with
lipofectamine 2000 was replaced with fresh complete
medium. Before use, 96 well plates were polylisinated
with poly-D-lysine. Luciferase assays were performed
using the Dual Reporter System (Promega Inc.). 24 hours
post-transfection, cells were lysed in the buffer provided
in the Promega Luciferase System. Dual luciferase assays
were performed according to the manufacturer's instruc-
tions, using a Mithras LB 940 luminometer (Berthold).
Relative luciferase activities were obtained by normalizing
the luciferase activity against Renilla luciferase activity.
Real Time PCR
Quantitative real-time PCR (qPCR) primers specific for
individual BCL2L11 exons and for total BCL2L11 tran-
scripts used were BCL2L11E1-FOR CCATGATTTCCCATT-
TCTCA, BCL2L11E1-REV GGCTTGTGCTGAAAGAAACA,
BCL2L11E2-FOR GCCACTACCACCACTTGATTCTT, BCL
2L11E2-REV AACCGAATACCGCGATGATG, BCL2L11-
1947F (5'-TGGATATTGTCAGGCCACTTG-3') and
BCL2L11-2018R (5'-CATAAGGAGCAGGCACAGAGAA-
3'). For normalization of Quantitative real-time PCR, β-
actin levels were determined in each sample using the fol-
lowing primers: β-actin-FOR CCTGGCACCCAGCACAAT
and  β-actin-REV GCCGATCCACACGGAGTACT. Real
time quantitative PCR analysis was carried out using an
iQ5 cycler machine (Biorad). Reactions were prepared in
triplicate using 2× SYBR Green Supermix (Biorad) accord-
ing to manufacturer's instructions to a final volume sam-
ple of 30 μl. The program used was the following: 95°C 3'
and 45 cycles at 95°C/30" and 55°C/30". For each exper-
iment, at least 2 independent electrophoresis runs were
performed.
Electrophoretic mobility shift assay (EMSA)
HEK293 were plated in 6 well plates and the day after
were transfected as describe before using 2.5 μg of E2F
plasmid or 2.5 μg of Bluescript plasmid. 24 hrs post-trans-
fection, cells were washed twice with PBS and harvested
for nuclear protein extraction according to the method of
Osborn et al. [16] with minor modifications. The protease
inhibitors leupeptin (10 μg/ml), antipain (5 μg/ml), and
pepstatin (5 μg/ml) and phenylmethylsulfonyl fluoride
(1 mM) were added. Protein concentration was measured
by the Coomassie assay (Pierce), using BSA as standard
protein. Binding reactions were carried out in a final vol-
ume of 20 μl using 8–10 μg nuclear extract according to
the conditions already specifically described for E2F1
binding site [20]. Radiolabelled probe was added last to
each reaction mixture and samples were incubated at
room temperature for 30 min. [7]. In a competition assays
a 50–100 × fold molar excess of unlabeled double-
stranded oligonucleotide was added to the reaction mix-
ture. Samples were then loaded onto a 5% (30:1:2) native
polyacrylamide gel in 45 mM Tris Base, 45 mM Sodium
borate, 10 mM EDTA ph 8 (0,5 × TBE) and run at 150 V,
dried, and exposed to Storage Phosphor Screen (Amer-
sham Biosciences). After overnight exposition, the image
was visualized by PhosphorImager SF (Molecular Dynam-
ics, Inc). Double stranded oligonucleotides were synthe-
sized, annealed to complementary synthetic
oligonucleotide in vitro and radiolabeled using T4 poly-
nucleotide kinase (Boeheringer) and [γ-32P] labelled ATP
(Perkin-Elmer, Inc.). Unincorporated nucleotides were
removed by Sephadex G-50 column chromatography
[19]. The following pairs of oligonucleotides were
employed (E2F sites underlined) E2F-1 P1 5'-AGTTC-
CCTCTGCGCGCCAGAGGGTG-3'. As cold competitor
were used the following oligonucleotids: E2F-1 C+ 5'-ATT
TAAGTTTCGCGCCCTTTCTCAA-3', E2F-1 P1 5'-AGTTC-
CCTCTGCGCGCCAGAGGGTG-3' and NF-κB 5'-AATGT-
GGGATTTTCCCATG-3'.
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